scholarly journals Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors

2017 ◽  
Vol 69 (2) ◽  
pp. 277-290 ◽  
Author(s):  
Roy Fleischmann ◽  
Janet van Adelsberg ◽  
Yong Lin ◽  
Geraldo da Rocha Castelar-Pinheiro ◽  
Jan Brzezicki ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Active Rheumatoid Arthritis ◽  
Inadequate Response ◽  
Tumor Necrosis Factor Inhibitors ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Disease Modifying ◽  
Necrosis Factor

scholarly journals Back to Basics: Prioritizing Communication as a Key Instrument in Managing Rheumatoid Arthritis

2021 ◽  
pp. jrheum.210984
Author(s):  
Paul Studenic ◽  
Helga Radner
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Therapy ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Inhibitors ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Synthetic Dmards ◽  
Disease Modifying ◽  
Necrosis Factor

Patients with rheumatoid arthritis (RA) have come to experience a tremendous increase in therapeutic options with disease-modifying antirheumatic drugs (DMARDs).1 After decades of dissatisfying drug therapy results with conventional synthetic DMARDs (csDMARDs) only, the introduction of the first tumor necrosis factor inhibitors in the late 1990s has revolutionized RA treatment.2

Sign in / Sign up

Export Citation Format

Share Document